Pharmaceutical industry in India
•Download as PPTX, PDF•
0 likes•408 views
This document summarizes the Indian pharmaceutical industry. It discusses the evolution and growth of the industry from the 1970s to present. It notes that India has the 3rd largest pharmaceutical industry by volume and is among the top 5 pharmaceutical markets globally. The document outlines the functions of pharmaceutical companies and factors driving the industry's growth. It also lists the top 10 pharmaceutical companies in India by sales and initiatives by the Indian government to support the industry. In conclusion, it discusses challenges and future growth opportunities for the Indian pharmaceutical sector.
Report
Share
Report
Share
Recommended
FDI IN PHARMACEUTICAL INDUSTRY IN INDIA
This document presents information on foreign direct investment (FDI) in India, with a focus on the pharmaceutical industry. It defines key terms like globalization, FDI, and portfolio investment. It describes the classification, objectives, advantages, and disadvantages of FDI. It provides data on FDI trends in India over time and top source countries. It also summarizes India's FDI policy and regulations, and analyzes FDI in the pharmaceutical industry specifically, including a SWOT analysis. The conclusion discusses the mostly positive impacts of FDI in India while noting some challenges remain.
Pharmaceutical industry in india
The pharmaceutical industry is comprised of organizations that perform scientific research to discover and develop new drugs and market medicines for human and animal health. The industry is based on research and development of medicines that prevent or treat diseases. The Indian pharmaceutical industry is among the top 10 markets globally and generated over $20 billion in revenue last year, expected to reach $26 billion by 2016. It produces drugs for various therapeutic areas and accounts for 1.4% of the global pharmaceutical market, ranking 3rd in production volume and 13th by production size. The market is expected to grow to $55 billion by 2020. India exports drugs to over 200 countries, with the US, EU, and Africa being top importers. Major Indian companies include Sun Ph
Pharma Sector of INDIA
a brief about the pharma sector of India..which company are working in the Indian market and what is their respective positions...
Supply chain issues in Pharma industry
This document discusses issues in the pharmaceutical supply chain. It outlines the life cycle of a pharmaceutical product from research to commercial manufacturing. It then describes the various components in the manufacturing and distribution chain from primary manufacturing to retailers. It notes challenges like the bullwhip effect, need to hold large active ingredient stocks, and lack of visibility beyond the first customer. Finally, it proposes steps to improve supply chain performance through increased visibility, reducing working capital, and ensuring efficiencies benefit all parties.
Pharmaceutical industry in india
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.
Pharmaceutical Offshoring Landscape A Syndicated Report
- The pharmaceutical industry is increasingly offshoring R&D activities to countries like India and China to take advantage of lower costs. India captured $125 million in offshored R&D spending in 2008 and China captured $375 million.
- India has become a major destination for clinical trials and data management due to its large, skilled talent pool and lower costs that are 20-30% of developed markets. The market for outsourced clinical trials in India is growing at 31% annually.
- Pharmaceutical companies are establishing facilities in India's Special Economic Zones which provide tax incentives and regulatory benefits to encourage further offshoring and foreign investment in the country.
Indian association of lady vets presentation
1. The Indian pharmaceutical industry is poised to take advantage of the size it has achieved through process patents and pursue new drug development opportunities in the large domestic and global markets.
2. India has a high intellectual capital workforce and low costs of drug development and clinical trials, providing opportunities for new drug introduction, R&D consolidation, and contract research.
3. While generics will still be a focus, companies are also investing in indigenous new drug development, natural products research, and licensing deals for new chemical entities.
Clinical Research In India
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
Recommended
FDI IN PHARMACEUTICAL INDUSTRY IN INDIA
This document presents information on foreign direct investment (FDI) in India, with a focus on the pharmaceutical industry. It defines key terms like globalization, FDI, and portfolio investment. It describes the classification, objectives, advantages, and disadvantages of FDI. It provides data on FDI trends in India over time and top source countries. It also summarizes India's FDI policy and regulations, and analyzes FDI in the pharmaceutical industry specifically, including a SWOT analysis. The conclusion discusses the mostly positive impacts of FDI in India while noting some challenges remain.
Pharmaceutical industry in india
The pharmaceutical industry is comprised of organizations that perform scientific research to discover and develop new drugs and market medicines for human and animal health. The industry is based on research and development of medicines that prevent or treat diseases. The Indian pharmaceutical industry is among the top 10 markets globally and generated over $20 billion in revenue last year, expected to reach $26 billion by 2016. It produces drugs for various therapeutic areas and accounts for 1.4% of the global pharmaceutical market, ranking 3rd in production volume and 13th by production size. The market is expected to grow to $55 billion by 2020. India exports drugs to over 200 countries, with the US, EU, and Africa being top importers. Major Indian companies include Sun Ph
Pharma Sector of INDIA
a brief about the pharma sector of India..which company are working in the Indian market and what is their respective positions...
Supply chain issues in Pharma industry
This document discusses issues in the pharmaceutical supply chain. It outlines the life cycle of a pharmaceutical product from research to commercial manufacturing. It then describes the various components in the manufacturing and distribution chain from primary manufacturing to retailers. It notes challenges like the bullwhip effect, need to hold large active ingredient stocks, and lack of visibility beyond the first customer. Finally, it proposes steps to improve supply chain performance through increased visibility, reducing working capital, and ensuring efficiencies benefit all parties.
Pharmaceutical industry in india
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.
Pharmaceutical Offshoring Landscape A Syndicated Report
- The pharmaceutical industry is increasingly offshoring R&D activities to countries like India and China to take advantage of lower costs. India captured $125 million in offshored R&D spending in 2008 and China captured $375 million.
- India has become a major destination for clinical trials and data management due to its large, skilled talent pool and lower costs that are 20-30% of developed markets. The market for outsourced clinical trials in India is growing at 31% annually.
- Pharmaceutical companies are establishing facilities in India's Special Economic Zones which provide tax incentives and regulatory benefits to encourage further offshoring and foreign investment in the country.
Indian association of lady vets presentation
1. The Indian pharmaceutical industry is poised to take advantage of the size it has achieved through process patents and pursue new drug development opportunities in the large domestic and global markets.
2. India has a high intellectual capital workforce and low costs of drug development and clinical trials, providing opportunities for new drug introduction, R&D consolidation, and contract research.
3. While generics will still be a focus, companies are also investing in indigenous new drug development, natural products research, and licensing deals for new chemical entities.
Clinical Research In India
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
Present Status and Scope of Pharmaceutical industry in India
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Analysis of Pharmaceutical Sector in India
The document analyzes the pharmaceutical sector in India. It discusses that India is a leading producer and exporter of pharmaceuticals, with the industry experiencing rapid growth. The annual turnover of the Indian pharmaceutical market increased from $16.41 billion in 2016 to $20.03 billion in 2019. The document outlines the evolution and growth of the sector over time, driven by government initiatives and increasing R&D spending. It provides an overview of major players like Sun Pharma and Cipla, including their history, operations, products and financial details. A SWOT analysis is also presented for the two companies.
Biotech & Pharma Market July 2009
The document discusses opportunities in the Indian pharmaceutical and biotechnology sectors. It outlines 8 subsectors: pharmaceuticals, biopharma, contract research organizations, industrial enzymes, agribiotech, bioinformatics, diagnostics, and lab supplies. The core pharmaceutical industry focuses on small molecule drugs and generics. The biotech industry includes bio-pharma, agriculture, bioinformatics and is growing at 30% annually. The Indian pharma/biotech market was estimated at $18 billion in 2008-2009 and is projected to continue strong growth across subsectors.
Pharmaceutical industry India
The Indian pharmaceutical industry has grown significantly over the past few decades from a market dominated by foreign companies to becoming a major exporter and the 4th largest producer by volume globally. It meets 95% of domestic medical needs through companies manufacturing generic drugs and drug intermediates. The industry is projected to grow at 8% annually to $34 billion by 2012, higher than global growth, driven by factors like rising incomes, health awareness, and increasing treatment of medical conditions. The government provides various incentives and export promotion initiatives to support the industry's continued growth and ability to capture opportunities in outsourcing and the global market.
Indian Pharmaceutical Industry
The document discusses India's pharmaceutical industry, including its current size and growth rate. It notes that formulations make up 79% of the industry while bulk drugs account for 21%. The background section outlines how India's Patents Act of 1970 only recognized process patents and led to increased domestic production. It also discusses how India transitioned to a product patent regime in 2005 to comply with TRIPS and how this has impacted multinational companies investing in India.
Eli lilly ranbaxy jv
Global pharmaceutical companies grew in the 1990s through forward and backward integration, while drug discovery became increasingly expensive. Indian pharmaceutical industries grew as well, but with lower per capita healthcare spending and a focus on generic drugs. In 1992, Eli Lilly and Ranbaxy Laboratories formed a 50-50% joint venture to allow Lilly to enter the Indian market using Ranbaxy's local knowledge, with both companies seeing opportunities in innovation and generics. The joint venture became profitable by 1996.
Research Project on Factors affecting Employees Satisfaction
A Summer Internship Project on Employee Satisfaction at Pharmaceutical Company Located near By Vadodara, Gujarat, India
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
PHARMACY EDUCATION AND PRACTISE - CHALLENGES TO MEET FUTURE PROFESSIONAL NEEDS
PHARMACY EDUCATION AND PRACTISE - CHALLENGES TO MEET FUTURE PROFESSIONAL NEEDSGlaxoSmithKline Pharma GmbH
The document discusses the history and evolution of the pharmaceutical industry in India. It notes that pharmacy education must adapt to meet future needs of the profession by integrating new technologies and ensuring adequate training. There is currently a shortage of pharmacists that is projected to worsen, and challenges include expanding faculty, training sites, and financing education programs. The pharmaceutical industry in India has grown significantly but still faces challenges in research and development. Government initiatives aim to support further growth, though foreign investment will also be important to meet future needs.Pharma industry 1-4_9_29_50
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Assignment on pharmachetucal company by neha, tanya, sameer
This document provides an overview of the pharmaceutical industry and three major Indian pharmaceutical companies - Ranbaxy, Dr. Reddy's, and Cipla. It discusses the history and origins of drugstores dating back to the Middle Ages. It then profiles the three companies, detailing their founding dates, financial information like revenues and market share, organizational structure including board of directors and number of employees, and strengths and weaknesses. The document also analyzes the Indian pharmaceutical sector and includes statistics on market size, production levels, and growth rates.
Indian pharmaceuticals-industry (1)
The document provides an overview of the pharmaceutical industry in India. It discusses the current state and growth of the industry. Some of the key points include:
- The Indian pharmaceutical industry is large and growing at 8-9% annually, currently worth $4.5 billion.
- Major players in the industry include Cipla, Ranbaxy, Dr. Reddy's, Sun Pharma, and Aurobindo Pharma.
- The government has introduced several initiatives to support the industry such as allowing 100% FDI and establishing a $639 million venture capital fund.
- The industry faces challenges of declining R&D productivity, patent expirations, and pricing issues but is expected
Growth of indian pharmaceuticals in the world market
The document provides an overview of the growth of the Indian pharmaceutical industry. It discusses factors that have contributed to the industry's growth, including low production costs, contract manufacturing, and research and development. It also outlines government policies that have supported the industry and notes that the industry is moving towards basic research and exporting generic drugs to markets like the US. While the industry was previously focused on domestic needs, exports now drive much of its growth. The transition to a new patent regime allowing product patents brings both opportunities and challenges to the evolving Indian pharmaceutical sector.
Pharmaceuticals Sector Report September 2017
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
Biocon case study group 1
Biocon India Group should expand its operations through Clinigene, its clinical research subsidiary, to capture opportunities in the growing clinical trials market in India. The summary is:
1) Clinigene should expand from bioequivalence and bioavailability studies into clinical trials over 2 years by developing expertise, recruiting qualified staff, and securing clinical trial projects.
2) Factors to consider include maintaining Biocon's public image on ethical issues, protecting its organizational culture, and avoiding expertise divergence from other Biocon operations.
3) A phased expansion over 2 years allows Clinigene to establish itself while Biocon drafts an expansion plan and scouts required resources, minimizing risks to its reputation and operations.
saurabh2
The Indian pharmaceutical industry has grown significantly over time and is expected to reach $45 billion by 2020, making it the 6th largest pharmaceutical market. It has evolved over four epochs from 1850 to the present. Currently, anti-infectives make up the largest part of the market. The industry faces major challenges including competition from large multinational companies and generic manufacturers, government price controls, lack of strong intellectual property protection, and managing drug portfolios. However, the industry also provides opportunities such as growth in exports, partnerships with multinationals, and clinical trials. The major players are Sun Pharma, Lupin, Cipla, Dr. Reddy's, and Aurobindo, and the government supports
Bio similar- An opportunities or challenge for Indian Company
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
Indian pharma outlook
The document discusses opportunities and challenges facing India's pharmaceutical industry. It notes that as drug patents expire, Indian generic drug producers are well-positioned to expand globally. It also discusses how India is becoming an attractive location for multinational drug companies to outsource research, development, and manufacturing activities due to its scientific expertise and lower costs. Further, India's large population represents a major potential domestic market, though expanding access to medicines is challenging. The industry now has opportunities for both foreign and domestic firms to partner and leverage each other's strengths for mutual benefit.
Biotech areas
The document discusses opportunities for cooperation and partnership in biotechnology between India and other countries. It notes that the Indian biotech industry has grown significantly in recent years but still has room for growth. Key opportunities for partnerships include contract research, manufacturing of biogenerics, clinical trials, and bioinformatics. The document outlines India's strengths in these areas like a skilled workforce, low costs, and bio-resources that make it an attractive partner for global biotech companies.
3.1 PHARMACEUTICAL MARKETING & PROMOTION.pdf
The global pharmaceutical manufacturing market is expected to grow significantly from 2017 to 2022 due to advantages of continuous manufacturing processes. The Indian pharmaceutical market is the third largest by volume and is a major exporter of generic drugs. The market is expected to grow to $55 billion by 2020 due to investments in production and R&D from companies and initiatives by the Indian government to promote pharmaceutical industry growth.
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
More Related Content
Similar to Pharmaceutical industry in India
Present Status and Scope of Pharmaceutical industry in India
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Analysis of Pharmaceutical Sector in India
The document analyzes the pharmaceutical sector in India. It discusses that India is a leading producer and exporter of pharmaceuticals, with the industry experiencing rapid growth. The annual turnover of the Indian pharmaceutical market increased from $16.41 billion in 2016 to $20.03 billion in 2019. The document outlines the evolution and growth of the sector over time, driven by government initiatives and increasing R&D spending. It provides an overview of major players like Sun Pharma and Cipla, including their history, operations, products and financial details. A SWOT analysis is also presented for the two companies.
Biotech & Pharma Market July 2009
The document discusses opportunities in the Indian pharmaceutical and biotechnology sectors. It outlines 8 subsectors: pharmaceuticals, biopharma, contract research organizations, industrial enzymes, agribiotech, bioinformatics, diagnostics, and lab supplies. The core pharmaceutical industry focuses on small molecule drugs and generics. The biotech industry includes bio-pharma, agriculture, bioinformatics and is growing at 30% annually. The Indian pharma/biotech market was estimated at $18 billion in 2008-2009 and is projected to continue strong growth across subsectors.
Pharmaceutical industry India
The Indian pharmaceutical industry has grown significantly over the past few decades from a market dominated by foreign companies to becoming a major exporter and the 4th largest producer by volume globally. It meets 95% of domestic medical needs through companies manufacturing generic drugs and drug intermediates. The industry is projected to grow at 8% annually to $34 billion by 2012, higher than global growth, driven by factors like rising incomes, health awareness, and increasing treatment of medical conditions. The government provides various incentives and export promotion initiatives to support the industry's continued growth and ability to capture opportunities in outsourcing and the global market.
Indian Pharmaceutical Industry
The document discusses India's pharmaceutical industry, including its current size and growth rate. It notes that formulations make up 79% of the industry while bulk drugs account for 21%. The background section outlines how India's Patents Act of 1970 only recognized process patents and led to increased domestic production. It also discusses how India transitioned to a product patent regime in 2005 to comply with TRIPS and how this has impacted multinational companies investing in India.
Eli lilly ranbaxy jv
Global pharmaceutical companies grew in the 1990s through forward and backward integration, while drug discovery became increasingly expensive. Indian pharmaceutical industries grew as well, but with lower per capita healthcare spending and a focus on generic drugs. In 1992, Eli Lilly and Ranbaxy Laboratories formed a 50-50% joint venture to allow Lilly to enter the Indian market using Ranbaxy's local knowledge, with both companies seeing opportunities in innovation and generics. The joint venture became profitable by 1996.
Research Project on Factors affecting Employees Satisfaction
A Summer Internship Project on Employee Satisfaction at Pharmaceutical Company Located near By Vadodara, Gujarat, India
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
PHARMACY EDUCATION AND PRACTISE - CHALLENGES TO MEET FUTURE PROFESSIONAL NEEDS
PHARMACY EDUCATION AND PRACTISE - CHALLENGES TO MEET FUTURE PROFESSIONAL NEEDSGlaxoSmithKline Pharma GmbH
The document discusses the history and evolution of the pharmaceutical industry in India. It notes that pharmacy education must adapt to meet future needs of the profession by integrating new technologies and ensuring adequate training. There is currently a shortage of pharmacists that is projected to worsen, and challenges include expanding faculty, training sites, and financing education programs. The pharmaceutical industry in India has grown significantly but still faces challenges in research and development. Government initiatives aim to support further growth, though foreign investment will also be important to meet future needs.Pharma industry 1-4_9_29_50
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Assignment on pharmachetucal company by neha, tanya, sameer
This document provides an overview of the pharmaceutical industry and three major Indian pharmaceutical companies - Ranbaxy, Dr. Reddy's, and Cipla. It discusses the history and origins of drugstores dating back to the Middle Ages. It then profiles the three companies, detailing their founding dates, financial information like revenues and market share, organizational structure including board of directors and number of employees, and strengths and weaknesses. The document also analyzes the Indian pharmaceutical sector and includes statistics on market size, production levels, and growth rates.
Indian pharmaceuticals-industry (1)
The document provides an overview of the pharmaceutical industry in India. It discusses the current state and growth of the industry. Some of the key points include:
- The Indian pharmaceutical industry is large and growing at 8-9% annually, currently worth $4.5 billion.
- Major players in the industry include Cipla, Ranbaxy, Dr. Reddy's, Sun Pharma, and Aurobindo Pharma.
- The government has introduced several initiatives to support the industry such as allowing 100% FDI and establishing a $639 million venture capital fund.
- The industry faces challenges of declining R&D productivity, patent expirations, and pricing issues but is expected
Growth of indian pharmaceuticals in the world market
The document provides an overview of the growth of the Indian pharmaceutical industry. It discusses factors that have contributed to the industry's growth, including low production costs, contract manufacturing, and research and development. It also outlines government policies that have supported the industry and notes that the industry is moving towards basic research and exporting generic drugs to markets like the US. While the industry was previously focused on domestic needs, exports now drive much of its growth. The transition to a new patent regime allowing product patents brings both opportunities and challenges to the evolving Indian pharmaceutical sector.
Pharmaceuticals Sector Report September 2017
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
Biocon case study group 1
Biocon India Group should expand its operations through Clinigene, its clinical research subsidiary, to capture opportunities in the growing clinical trials market in India. The summary is:
1) Clinigene should expand from bioequivalence and bioavailability studies into clinical trials over 2 years by developing expertise, recruiting qualified staff, and securing clinical trial projects.
2) Factors to consider include maintaining Biocon's public image on ethical issues, protecting its organizational culture, and avoiding expertise divergence from other Biocon operations.
3) A phased expansion over 2 years allows Clinigene to establish itself while Biocon drafts an expansion plan and scouts required resources, minimizing risks to its reputation and operations.
saurabh2
The Indian pharmaceutical industry has grown significantly over time and is expected to reach $45 billion by 2020, making it the 6th largest pharmaceutical market. It has evolved over four epochs from 1850 to the present. Currently, anti-infectives make up the largest part of the market. The industry faces major challenges including competition from large multinational companies and generic manufacturers, government price controls, lack of strong intellectual property protection, and managing drug portfolios. However, the industry also provides opportunities such as growth in exports, partnerships with multinationals, and clinical trials. The major players are Sun Pharma, Lupin, Cipla, Dr. Reddy's, and Aurobindo, and the government supports
Bio similar- An opportunities or challenge for Indian Company
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
Indian pharma outlook
The document discusses opportunities and challenges facing India's pharmaceutical industry. It notes that as drug patents expire, Indian generic drug producers are well-positioned to expand globally. It also discusses how India is becoming an attractive location for multinational drug companies to outsource research, development, and manufacturing activities due to its scientific expertise and lower costs. Further, India's large population represents a major potential domestic market, though expanding access to medicines is challenging. The industry now has opportunities for both foreign and domestic firms to partner and leverage each other's strengths for mutual benefit.
Biotech areas
The document discusses opportunities for cooperation and partnership in biotechnology between India and other countries. It notes that the Indian biotech industry has grown significantly in recent years but still has room for growth. Key opportunities for partnerships include contract research, manufacturing of biogenerics, clinical trials, and bioinformatics. The document outlines India's strengths in these areas like a skilled workforce, low costs, and bio-resources that make it an attractive partner for global biotech companies.
3.1 PHARMACEUTICAL MARKETING & PROMOTION.pdf
The global pharmaceutical manufacturing market is expected to grow significantly from 2017 to 2022 due to advantages of continuous manufacturing processes. The Indian pharmaceutical market is the third largest by volume and is a major exporter of generic drugs. The market is expected to grow to $55 billion by 2020 due to investments in production and R&D from companies and initiatives by the Indian government to promote pharmaceutical industry growth.
Similar to Pharmaceutical industry in India (20)
Present Status and Scope of Pharmaceutical industry in India
Present Status and Scope of Pharmaceutical industry in India
Research Project on Factors affecting Employees Satisfaction
Research Project on Factors affecting Employees Satisfaction
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
PHARMACY EDUCATION AND PRACTISE - CHALLENGES TO MEET FUTURE PROFESSIONAL NEEDS
PHARMACY EDUCATION AND PRACTISE - CHALLENGES TO MEET FUTURE PROFESSIONAL NEEDS
Assignment on pharmachetucal company by neha, tanya, sameer
Assignment on pharmachetucal company by neha, tanya, sameer
Growth of indian pharmaceuticals in the world market
Growth of indian pharmaceuticals in the world market
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
Recently uploaded
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Introduction to AI for Nonprofits with Tapp Network
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
PCOS corelations and management through Ayurveda.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxMohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
DRUGS AND ITS classification slide share
Any substance (other than food) that is used to prevent, diagnose, treat, or relieve symptoms of a
disease or abnormal condition
Top five deadliest dog breeds in America
Thinking of getting a dog? Be aware that breeds like Pit Bulls, Rottweilers, and German Shepherds can be loyal and dangerous. Proper training and socialization are crucial to preventing aggressive behaviors. Ensure safety by understanding their needs and always supervising interactions. Stay safe, and enjoy your furry friends!
Assessment and Planning in Educational technology.pptx
In an education system, it is understood that assessment is only for the students, but on the other hand, the Assessment of teachers is also an important aspect of the education system that ensures teachers are providing high-quality instruction to students. The assessment process can be used to provide feedback and support for professional development, to inform decisions about teacher retention or promotion, or to evaluate teacher effectiveness for accountability purposes.
Main Java[All of the Base Concepts}.docx
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
Advanced Java[Extra Concepts, Not Difficult].docx
This is part 2 of my Java Learning Journey. This contains Hashing, ArrayList, LinkedList, Date and Time Classes, Calendar Class and more.
Types of Herbal Cosmetics its standardization.
Physiology and chemistry of skin and pigmentation, hairs, scalp, lips and nail, Cleansing cream, Lotions, Face powders, Face packs, Lipsticks, Bath products, soaps and baby product,
Preparation and standardization of the following : Tonic, Bleaches, Dentifrices and Mouth washes & Tooth Pastes, Cosmetics for Nails.
How to Add Chatter in the odoo 17 ERP Module
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)Academy of Science of South Africa
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.Recently uploaded (20)
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
Assessment and Planning in Educational technology.pptx
Assessment and Planning in Educational technology.pptx
Film vocab for eal 3 students: Australia the movie
Film vocab for eal 3 students: Australia the movie
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Pharmaceutical industry in India
- 1. Presented By :- Guided by:- Ms. Rupali Gole Mr. Ravi Sahu Sir Ms. Neha Kadu Mr. Sarvesh Rathi Sir Ms. Shireen Bobade 1
- 2. 2
- 3. CONTENTS:- Introduction Of Pharmaceutical Industry Indian Pharmaceutical Evolution Significance of Pharma Industry Function of Pharma Companies Why Pharma Industry Grow Major Pharmaceutical Companies in India Government Initiatives and Investments Challenge and Future Growth Opportunity 3
- 4. IPI is worlds 3rd largest in terms of volume and 14th terms of value. Top 5th pharma market globally. Domestic pharma market Rs.6370 corer (US.$1.03 bn) IPI is estimated to be worth US.$4.5 bn. 20000 registered units,250 large units and 8000 small scale units. Source ;- www.cci.in 4
- 5. Phase I 1970 :- 1) Market share domination by foreign companies. 2) Relative absence of organized India companies. Phase II 1980 Government Control :- 1) Indian patent act – 1970 2) Drug price capped 3) Local companies begin to make an impact Source;- www.carerating.co 5
- 6. Phase III 1990 Development Phase :- 1) Process development 2) Production infrastructure creation 3) Export initiatives Phase IV 2000 Growth Phase :- 1)Rapid expansion of domestic market 2) International Market development 3) Research Orientation Phase V 2010 Innovation and Research 1)New IP Law 2)Discovery Research 3)Convergence Source;- www.camrerating.co 6
- 7. Competent workforce Cost-effective chemical synthesis Legal & Financial Framework Information & Technology Globalization Source;- Wikipedia 7
- 8. FOUR MAJOR FUNCTIONS: 1. Research and Development 2. Regulators 3. Production 4. Quality 5. Marketing 8
- 9. Increasing a medical facilities Increasing chronic diseases Increasing in health insurance coverage Good Manufacturing Practices (GMP) (WHO GMP Protocols) Good Clinical Practices (GCP) Good laboratory Practices (GLP) Source;- www.cdsco.nic.in 9
- 10. 196 23 14 14 14 13 12 11 7 0 50 100 150 200 250 Chart Title Column1 Source;-Mckinsey India and company 10
- 11. Company Name Sales in INR billion Cipla 69.77 Ranbaxy Lab 76.86 Dr. Reddy’s Labs 66.86 Sun Pharma 40.15 Lupin Ltd. 53.64 Aurobindo Pharma 42.84 Jubilant Life 26.41 Cadila Health 31.52 Ipca Labs 23.52 Wockhardt 26.50 Source;- www.cci.in 11
- 12. Established a various Organization Tax incentives & grants for Biotech start up and firms. The Ministry of Health & Family Welfare examines pharmaceutical issues. It established the Department of Biotechnology in 1986 under the Ministry of Science and Technology. Source;-www.cdsco.nic.in). 12
- 13. Indian Pharma industry would have to contend several challenges particularly I. Effects of new product patent II. Drugs price control III. Regulatory reforms IV. Infrastructure development V. Quality management VI. Conformance to global standards 13
- 14. 14
- 15. 15
- 16. 16